Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 613-622

  Nowell, Mari A ^a   Williams, Anwen S ^a   Carty, Sarah A ^a   Scheller, Jürgen ^b   Hayes, Anthony J ^c   Jones, Gareth W ^a   Richards, Peter J ^a   Slinn, Simon ^a   Ernst, Matthias ^d   Jenkins, Brendan J ^e   Topley, Nicholas ^a   Rose John, Stefan ^b   Jones, Simon A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF KIEL   (Germany)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^e HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 17; INTERLEUKIN 6; STAT3 PROTEIN; AUTACOID; HYBRID PROTEIN; IL6ST PROTEIN, MOUSE; SGP130FC PROTEIN; STAT3 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LEUKOCYTE; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNOVIUM; T LYMPHOCYTE; TH17 CELL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CHO CELL; CRICETULUS; DBA MOUSE; DRUG ANTAGONISM; GENETICS; HAMSTER; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; RECURRENT DISEASE; TRANSGENIC MOUSE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; CYTOKINE RECEPTOR GP130; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; RECURRENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE; T-LYMPHOCYTES;

EID: 59849091830     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.613     Document Type: Article

References (53)

1. Jones, S. A. 2005. Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 175: 3463-3468.
2. Rose-John, S., J. Scheller, G. Elson, and S. A. Jones. 2006. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukocyte Biol. 80: 227-236.
3. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
4. + T helper cells. Cell 126: 1121-1133.
5. H17 lineage. Nature 441: 231-234.
6. + T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
7. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189.
8. Veldhoen, M., R. J. Hocking, R. A. Flavell, and B. Stockinger. 2006. Signals mediated by transforming growth factor-β initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat. Immunol. 7: 1151-1156.
9. Kallen, K. J. 2002. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim. Biophys. Acta 1592: 323-343.
10. Heinrich, P. C., I. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen, and F. Schaper. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374: 1-20.
11. McInnes, I. B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7: 429-442.
12. Choy, E. H., D. A. Isenberg, T. Garrood, S. Farrow, Y. Ioannou, H. Bird, N. Cheung, B. Williams, B. Hazleman, R. Price, et al. 2002. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46: 3143-3150.
13. Ito, H., M. Takazoe, Y. Fukuda, T. Hibi, K. Kusugami, A. Andoh, T. Matsumoto, T. Yamamura, J. Azuma, N. Nishimoto, et al. 2004. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126: 989-996, discussion 947.
14. Nakahara, H., J. Song, M. Sugimoto, K. Hagihara, T. Kishimoto, K. Yoshizaki, and N. Nishimoto. 2003. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 48: 1521-1529.
15. Nishimoto, N., Y. Kanakura, K. Aozasa, T. Johkoh, M. Nakamura, S. Nakano, N. Nakano, Y. Ikeda, T. Sasaki, K. Nishioka, et al. 2005. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106: 2627-2632.
16. Nishimoto, N., and T. Kishimoto. 2006. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2: 619-626.
17. Yoshizaki, K., N. Nishimoto, M. Mihara, and T. Kishimoto. 1998. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin. Immunopathol. 20: 247-259.
18. Diao, H., and M. Kohanawa. 2005. Endogenous interleukin-6 plays a crucial protective role in streptococcal toxic shock syndrome via suppression of tumor necrosis factor α production. Infect. Immun. 73: 3745-3748.
19. + T-cells. PLOS Pathogens. 4: e1000006.
20. Onogawa, T. 2005. Local delivery of soluble interleukin-6 receptors to improve the outcome of α-toxin producing Staphylococcus aureus infection in mice. Immunobiology 209: 651-660.
21. Atreya, R., J. Mudter, S. Finotto, J. Mullberg, T. Jostock, S. Wirtz, M. Schutz, B. Bartsch, M. Holtmann, C. Becker, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6: 583-588.
22. Hurst, S. M., T. S. Wilkinson, R. M. McLoughlin, S. Jones, S. Horiuchi, N. Yamamoto, S. Rose-John, G. M. Fuller, N. Topley, and S. A. Jones. 2001. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705-714.
23. Jostock, T., J. Mullberg, S. Ozbek, R. Atreya, G. Blinn, N. Voltz, M. Fischer, M. F. Neurath, and S. Rose-John. 2001. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268: 160-167.
24. McLoughlin, R. M., S. M. Hurst, M. A. Nowell, D. A. Harris, S. Horiuchi, L. W. Morgan, T. S. Wilkinson, N. Yamamoto, N. Topley, and S. A. Jones. 2004. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J. Immunol. 172: 5676-5683.
25. McLoughlin, R. M., B. J. Jenkins, D. Grail, A. S. Williams, C. A. Fielding, C. R. Parker, M. Ernst, N. Topley, and S. A. Jones. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc. Natl. Acad. Sci. USA 102: 9589-9594.
26. McLoughlin, R. M., J. Witowski, R. L. Robson, T. S. Wilkinson, S. M. Hurst, A. S. Williams, J. D. Williams, S. Rose-John, S. A. Jones, and N. Topley. 2003. Interplay between IFN-γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J. Clin. Invest. 112: 598-607.
27. Nowell, M. A., P. J. Richards, S. Horiuchi, N. Yamamoto, S. Rose-John, N. Topley, A. S. Williams, and S. A. Jones. 2003. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 171: 3202-3209.
28. Rabe, B., A. Chalaris, U. May, G. H. Waetzig, D. Seegert, A. S. Williams, S. A. Jones, S. Rose-John, and J. Scheller. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111: 1021-1028.
29. Richards, P. J., M. A. Nowell, S. Horiuchi, R. M. McLoughlin, C. A. Fielding, S. Grau, N. Yamamoto, M. Ehrmann, S. Rose-John, A. S. Williams, et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum. 54: 1662-1672.
30. Desgeorges, A., C. Gabay, P. Silacci, D. Novick, P. Roux-Lombard, G. Grau, J. M. Dayer, T. Vischer, and P. A. Guerne. 1997. Concentrations and origins of soluble interleukin 6 receptor-α in serum and synovial fluid. J. Rheumatol. 24: 1510-1516.
31. Kotake, S., K. Sato, K. J. Kim, N. Takahashi, N. Udagawa, I. Nakamura, A. Yamaguchi, T. Kishimoto, T. Suda, and S. Kashiwazaki. 1996. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11: 88-95.
32. Robak, T., A. Gladalska, H. Stepien, and E. Robak. 1998. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediat. Inflamm. 7: 347-353.
33. Jenkins, B. J., D. Grail, T. Nheu, M. Najdovska, B. Wang, P. Waring, M. Inglese, R. M. McLoughlin, S. A. Jones, N. Topley, et al. 2005. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling. Nat. Med. 11: 845-852.
34. Tebbutt, N. C., A. S. Giraud, M. Inglese, B. Jenkins, P. Waring, F. J. Clay, S. Malki, B. M. Alderman, D. Grail, F. Hollande, et al. 2002. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 8: 1089-1097.
35. Ohshima, S., Y. Saeki, T. Mima, M. Sasai, K. Nishioka, S. Nomura, M. Kopf, Y. Katada, T. Tanaka, M. Suemura, and T. Kishimoto. 1998. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl. Acad. Sci. USA 95: 8222-8226.
36. Wong, P. K., J. M. Quinn, N. A. Sims, A. van Nieuwenhuijze, I. K. Campbell, and I. P. Wicks. 2006. Interleukin-6 modulates production of T lymphocytederived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 54: 158-168.
37. Bennett, J. C. 1978. The infectious etiology of rheumatoid arthritis: new considerations. Arthritis Rheum. 21: 531-538.
38. Nowell, M. A., P. J. Richards, C. A. Fielding, S. Ognjanovic, N. Topley, A. S. Williams, G. Bryant-Greenwood, and S. A. Jones. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 transsignaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 54: 2084-2095.
39. Miossec, P. 2007. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum. 56: 2111-2115.
40. Acosta-Rodriguez, E. V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. Lanzavecchia, F. Sallusto, and G. Napolitani. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8: 639-646.
41. Hirota, K., H. Yoshitomi, M. Hashimoto, S. Maeda, S. Teradaira, N. Sugimoto, T. Yamaguchi, T. Nomura, H. Ito, T. Nakamura, et al. 2007. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. 204: 2803-2812.
42. - phenotype. J. Immunol. 178: 7525-7529.
43. Shuai, K., and B. Liu. 2003. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3: 900-911.
44. Croker, B. A., D. L. Krebs, J. G. Zhang, S. Wormald, T. A. Willson, E. G. Stanley, L. Robb, C. J. Greenhalgh, I. Forster, B. E. Clausen, et al. 2003. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4: 540-545.
45. Shouda, T., T. Yoshida, T. Hanada, T. Wakioka, M. Oishi, K. Miyoshi, S. Komiya, K. Kosai, Y. Hanakawa, K. Hashimoto, et al. 2001. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating in-flammatory arthritis. J. Clin. Invest. 108: 1781-1788.
46. Suzuki, A., T. Hanada, K. Mitsuyama, T. Yoshida, S. Kamizono, T. Hoshino, M. Kubo, A. Yamashita, M. Okabe, K. Takeda, et al. 2001. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med. 193: 471-481.
47. Chen, Q., D. T. Fisher, K. A. Clancy, J. M. Gauguet, W. C. Wang, E. Unger, S. Rose-John, U. H. von Andrian, H. Baumann, and S. S. Evans. 2006. Feverrange thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat. Immunol. 7: 1299-1308.
48. Curnow, S. J., D. Scheel-Toellner, W. Jenkinson, K. Raza, O. M. Durrani, J. M. Faint, S. Rauz, K. Wloka, D. Pilling, S. Rose-John, et al. 2004. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J. Immunol. 173: 5290-5297.
49. + Treg development and function during allergic airway inflammation in vivo. J. Clin. Invest. 115: 313-325.
50. +CD25 T cells. J. Immunol. 179: 2041-2045.
51. Becker, C., M. C. Fantini, C. Schramm, H. A. Lehr, S. Wirtz, A. Nikolaev, J. Burg, S. Strand, R. Kiesslich, S. Huber, et al. 2004. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501.
52. + central memory T cells. J. Exp. Med. 200: 725-735.
53. Coles, B., C. A. Fielding, S. Rose-John, J. Scheller, S. A. Jones, and V. B. O'Donnell. 2007. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am. J. Pathol. 171: 315-325.